Search results for Pacira Biosciences

Pacira BioSciences, Inc. 2026 Q1 - Results - Earnings Call Presentation

Form 144 Pacira BioSciences For: 23 April

Pacira BioSciences' CFO Sold 12,941 Shares for $326,000 Before Its Q1 Earnings Release

Pacira BioSciences, a leader in non-opioid pain management, reported a notable insider sale amid ongoing option exercise activity.

Real-World Data on EXPAREL® Shows Reduced Opioid Use and Lower Total Medical Costs in Medicare Patients Undergoing Tota...

BioDelivery Sciences Int’l, Inc. v. Alvogen PB Research & Development LLC

This case was filed in 2018 when Alvogen submitted to the FDA an ANDA for approval to market generic Belbuca, a buprenorphine buccal film used to administer the drug transmucosally...

Ensysce Biosciences Reports First Quarter 2026 Financial Results

~ IRB Approval Secured for PF614-MPAR-102 Part 3 ~~ Clinical Peer-Reviewed Data Published for First Overdose Protected Opioid PF614-MPAR®; Patent Estate Expanded ~~ Company Launche...

A year after Vertex’s big launch, pain drug research faces a pivotal moment

Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?

Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study

~ Advances First-in-Class Opioid with Oral Overdose-Protection ~

Cerapedics Announces Supplier Agreement with Vizient for PearlMatrixВ® P-15 Peptide Enhanced Bone Graft

<![CDATA[Travere Therapeutics’ Filspari Receives Full FDA Approval ]]>

Cerapedics Announces Supplier Agreement with Vizient for PearlMatrix® P-15 Peptide Enhanced Bone Graft

Agreement expands access to the Cerapedics portfolio of peptide-powered drug-device products for spinal fusion procedures WESTMINSTER, Colo., April 27,…

Pain division future

Pain division future Anonymous (not verified) Tue, 04/14/2026 - 05:06 field_thread_url https://cafepharma.com/boards/threads/pain-division-future.709242/...

Pain division future

Pain division future Anonymous (not verified) Wed, 05/13/2026 - 11:24 field_thread_url https://cafepharma.com/boards/threads/pain-division-future.709242/...

Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam

~ Chemical Control, Clinical Confidence: Rethinking Opioids ~

Pfizer deals extend patent life for a top-selling rare disease drug

Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have implications for others, including BridgeBio Pharma and Alnylam. 

UCB Staves Off Seizure Drug Competition After Bench Trial

UCB Inc. has persuaded a Delaware federal judge to uphold patents covering its seizure medication Nayzilam, a major win given that generic-drug maker Cipla Ltd. already admitted to...

<![CDATA[Pharmaceutical Executive Daily: Neurocrine Biosciences Agrees to Acquire Soleno Therapeutics]]>

Neurocrine to acquire Prader-Will drug in $2.9B Soleno buyout

The deal hands Neurocrine a “controversial” medicine, Vykat, that achieved $190 million in sales last year but faces persistent questions about its growth trajectory and safety, ac...

Bausch, MSN Laboratories Settle Patent Battle Over IBS Drug

Bausch Health and MSN Laboratories have ended their New Jersey patent fight over the irritable bowel medication Trulance after reaching a confidential settlement, filing a stipulat...

Parabilis, fresh from inking Regeneron pact, plans IPO to fund tumor drug’s phase 3 push

With the ink barely dry on an antibody-drug conjugate-style deal with Regeneron, Parabilis Medicines has now turned its attention to the public markets.

PainTEQ Launches TRAQв„ў, A Next-Generation Posterior Approach to SI Joint Fusion

A migraine drugmaker heads to the public markets through reverse merger

Mentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can treat migraines that aren’t well controlled by existing...

<![CDATA[Rigel Pharmaceuticals Enters $85 Million Agreement for Exclusive Global Rights to Veppanu]]>

Medtronic announces intent to acquire SPR Therapeutics, Inc., expanding care options for people living with chronic pain